The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 28284804 |
56 |
Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus. |
Merck |
| 24239482 |
9 |
Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemia. |
Pfizer |
| 23089526 |
21 |
The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus. |
Pfizer |
| 22196621 |
17 |
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus. |
Pfizer |
| 20472448 |
25 |
Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl)propanamides as glucokinase activators. |
Chinese Academy Of Sciences |
| 15713416 |
30 |
Glucokinase-activating ureas. |
Osi Pharmaceuticals |
Search and Browse
